Psychosocial interventions for people with both severe mental illness and substance misuse

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Hunt, Glenn E ^a   Siegfried, Nandi ^b   Morley, Kirsten ^a   Sitharthan, Thiagarajan ^a   Cleary, Michelle ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; CANNABIS USE; COGNITIVE BEHAVIORAL THERAPY; COMPARATIVE EFFECTIVENESS; DEATH; DISEASE SEVERITY; FUNCTIONAL STATUS; HUMAN; LIFE SATISFACTION; MENTAL DISEASE; MOTIVATIONAL INTERVIEWING; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; THERAPY EFFECT; ADDICTION; COGNITIVE THERAPY; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; MENTAL DISORDERS; SUBSTANCE-RELATED DISORDERS;

COGNITIVE THERAPY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MENTAL DISORDERS; MOTIVATIONAL INTERVIEWING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84899617951     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001088.pub3     Document Type: Review

References (358)

1. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al.Evaluation of a motivational interview for substance use within psychiatric inpatient services. Addiction 2002;97(10):1329-38.
2. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al.Motivational interviewing among psychiatric inpatients with substance use disorders. Acta Psychiatrica Scandinavica 2002;106(3):233-40.
3. Baker A, Bucci S, Kay-Lambkin F. Intervention for alcohol, cannabis and amphetamine use among people with a psychotic illness. NDARC Technical Report No. 193. Sydney: National Drug and Alcohol Research Centre, 2004:1-100. [: ISBN:1 887027 84 7]
4. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders - Randomised controlled trial. British Journal of Psychiatry 2006;188(5):439-48.
5. Baker A, Bucci S, Lewin TJ, Richmond R, Carr VJ. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Research 2005;134(3):241-50.
6. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al.Randomized controlled trial of motivational interviewing, cognitive behavior therapy and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry 2001;158(10):1706-13.
7. Haddock G. Dual diagnosis project: evaluation of family support and cognitive behaviour therapy for recent onset schizophrenia sufferers with substance misuse problems. National Research Register 2001; Vol. 1. [: N0244032344]
8. Haddock G, Barrowclough C, Tarrier N, Moring J, O'Brien R, Schofield N, et al.Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry 2003;183(November):418-26.
9. Barrowclough C. A pilot study to assess the impact of motivational intervention on schizophrenia patients with associated substance misuse. National Research Register 2004; Vol. 3:1-4.
10. Barrowclough C. A randomized controlled trial of integrated motivational interviewing and cognitive behavior therapy (mi-cbt) for people with a schizophrenia diagnosis and substance misuse - the MIDAS trial. Schizophrenia Bulletin 2011;37 Suppl 1:295.
11. Barrowclough C. An evaluation of motivational (MI) plus cognitive therapy (CBT) for schizophrenia and substance misuse. http://www.controlled-trials.com 2003.
12. Barrowclough C. An evaluation of motivational interventions (MI) plus cognitive behaviour therapy (CBT) for schizophrenia and substance misuse - MIDAS. National Research Register 2004; Vol. 1.
13. Barrowclough C, Haddock G, Beardmore R, Conrod P, Craig T, Davies L, et al.Evaluating integrated MI and CBT for people with psychosis and substance misuse: recruitment, retention and sample characteristics of the MIDAS trial. Addictive Behaviors 2009;34(10):859-66.
14. Barrowclough C, Haddock G, Fitzsimmons M, Johnson R. Treatment development for psychosis and co-occurring substance misuse: a descriptive review. Journal of Mental Health 2006;15(6):619-32.
15. Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, et al.Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 2010;341(7784):6325. [MEDLINE: 21106618]
16. Barrowclough C, Meier P, Beardmore R, Emsley R. Predicting therapeutic alliance in clients with psychosis and substance misuse. Journal of Nervous and Mental Disease 2010;198(5):373-7.
17. Haddock G, Beardmore R, Earnshaw P, Fitzsimmons M, Nothard S, Butler R, et al.Assessing fidelity to integrated motivational interviewing and CBT therapy for psychosis and substance use: the MI-CBT fidelity scale (MI-CTS). Journal of Mental Health 2012;21(1):38-48 2012;21(1):38-48.
18. Hartley S, Haddock G, Barrowclough C. Anxiety and depression and their links with delusions and hallucinations in people with a dual diagnosis of psychosis and substance misuse: A study using data from a randomised controlled trial. Behaviour Research and Therapy 2012;50(1):65-71.
19. Johnson R. MIDAS - mental health clinical trials - information for service users and carers. http://www.controlled-trials.com/ 2005.
20. Shabaruddin FH, Davies LM. Cost of delivering psychiatric inpatient care to mental health patients with psychosis and co-occuring substance use: A UK based study. Value in Health 2011;14:A291.
21. Bechdolf A, Pohlmann B, Guttgemanns J, Geyer C, Lindner K, Ferber C, et al.State-dependent motivational interviewing for people with schizophrenia and substance use: Results of a randomised controlled trial [Motivationsbehandlung für patienten mit der doppeldiagnose psychose und sucht]. Nervenarzt 2011;83(7):888-96. [MEDLINE: 21720841]
22. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental iIlness. Archives of General Psychiatry 2006;63(4):426-32.
23. Brown CH, Bennett ME, Li L, Bellack AS. Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders. Addictive Behaviors 2011;36(5):439-47.
24. Bond GR, McDonel EC, Miller LD, Pensec M. Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial Rehabilitation Journal 1991;15(2):31-43.
25. Bond GR, McDonel EC, Miller LD, Pensec M. Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial Rehabilitation Journal 1991;15(2):31-43.
26. Bonsack C. Motivational intervention to reduce cannabis use in young people with psychosis: A randomized controlled trial. Early Intervention in Psychiatry 2010;4 Suppl 1:159.
27. Bonsack C, Manetti SG, Favrod J, Montagrin Y, Besson J, Bovet P, et al.Motivational intervention to reduce cannabis use in young people with psychosis: A randomized controlled trial. Psychotherapy and Psychosomatics 2011;80(5):287-97.
28. Burnam MA, Morton SC, McGlynn EA, Peterson LP, Stecher BM, Hayes C, Vaccaro JV. An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. Journal of Addictive Diseases 1995;14(4):111-34.
29. McGlynn EA, Boynton J, Morton SC, Stecher BM, Hayes C, Vaccaro JV, Burnam MA. Treatment for the dually diagnosed homeless: program models and implementation experience: Los Angeles. Alcohol Treatment Quarterly 1993;10(3-4):171-86.
30. Chandler D, Spicer G. Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders. Community Mental Health Journal 2006;42(4):405-25.
31. Drake RE, Morrissey JP, Mueser KT. The challenge of treating forensic dual diagnosis clients: comment on "Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders". Community Mental Health Journal 2006;42(4):427-32.
32. Clark RE, Teague GB, Ricketts SK, Bush PW, Xie H, McGuire TG, et al.Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Services Research 1998;33(5):1285-8.
33. Drake RE. Ten year follow up of dual diagnosis treatment. CRISP database accessed 10/05/02 2002.
34. Drake RE, McHugo GJ, Clark RE, Teague GB, Xie H, Miles K. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. American Journal of Orthopsychiatry 1998;68(2):201-15.
35. Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, McGorry PD. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica 2006;114(2):109-17.
36. Essock SM, Mueser KT, Drake RE, Covell NH, McHugo GJ, Frisman LK, et al.Comparison of ACT and Standard Case Management for Delivering Integrated Treatment for Co-occurring Disorders. Psychiatric Services 2006;57(2):185-96.
37. Kanter J. Clinical case management, case management and ACT. Psychiatric Services 2006; Vol. 57, issue 4:578.
38. Manuel JI. A longitudinal analysis of psychiatric medication adherence and provider continuity among individuals with co-occurring disorders. Dissertation Abstracts International Section A: Humanities and Social Sciences 2009;69(10A):4126.
39. Manuel JI, Covell NH, Jackson CT, Essock SM. Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders?. Journal of the American Psychiatric Nurses Association 2011;17(1):51-6.
40. Godley SH, Hoewing-Roberson R, Godley MD. Final MISA Report. Bloomington, IN: Lighthouse Institute, 1994.
41. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Mental Health Journal 2003;39(3):189-202.
42. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. American Journal on Addictions 1995;4(1):33-42.
43. Hellerstein DJ, Rosenthal RN, Miner CR. Integrating services for schizophrenia and substance abuse. Psychiatric Quarterly 2001;72(4):291-306.
44. Hickman ME. The effects of personal feedback on alcohol intake in dually diagnosed clients: an empirical study of William R. Miller's motivational enhancement therapy. Unpublished thesis. University Graduate School, Dept. Counseling Psychology, Indiana University 1997.
45. Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M. CapOpus. randomized clinical trial: Specialized addiction treatment (MI & CBT) versus treatment as usual for young patients with cannabis abuse and psychosis. Early Intervention in Psychiatry 2010;4 Suppl 1:159.
46. Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M. CapOpus. randomized clinical trial: Specialized addiction treatment (MI & CBT) versus treatment as usual for young patients with cannabis abuse and psychosis. Early Intervention in Psychiatry 2010;4 Suppl 1:160.
47. Hjorthaj CR. Validity of self-reported cannabis use as measured by the timeline follow-back instrument in a trial randomizing people with comorbid cannabis use disorder and schizophrenia spectrum disorder. Early Intervention in Psychiatry 2010;4 Suppl 1:160.
48. Hjorthoj C, Fohlmann A, Larsen A-M, Madsen MTR, Vesterager L, Gluud C, et al.Design paper: the CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Trials 2008;9:42.
49. Hjorthoj CR, Fohlmann A, Larsen A-M, Madsen MTR, Vesterager L, Gluud C, et al.Interim analysis of the CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. Schizophrenia Research 2010;117(2-3):190.
50. Hjorthoj CR, Fohlmann A, Larsen AM, Arendt M, Nordentoft M. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (tlfb)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 2011;107(6):1123-31. [MEDLINE: 22151583]
51. Hjorthoj CR, Vesterager L, Nordentoft M. Test-retest reliability of the Danish adult reading test in patients with comorbid psychosis and cannabis-use disorder. Nordic Journal of Psychiatry 2013;67(3):159-63. [MEDLINE: 22624828]
52. Hjorthøj CR, Fohlmann A, Larsen A-M, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychological Medicine 2013;43(7):1499-1510. [PUBMED: 23040144]
53. NCT00484302. Cannabis and psychosis randomized clinical trial: specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. http://www.clinicaltrials.gov 2007.
54. Nordentoft M, Hjorthoj C, Fohlmann A. Capopus trial: An observer-blinded rct of specialized addiction treatment versus standard treatment for young patients with cannabis. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal 2009;24:S1178.
55. Jerrell JM. Cost-effective treatment for persons with dual disorders. New Directions for Mental Health Services 1996;70(Summer):79-91.
56. Jerrell JM, Hu TW, Ridgely MS. Cost-effectiveness of substance disorder interventions for people with severe mental illness. Journal of Mental Health Administration 1994;21(3):283-97.
57. Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. Journal of Nervous and Mental Disease 1995;183(9):566-76.
58. Jerrell JM, Ridgely MS. Impact of robustness of program implementation on outcomes of clients in dual diagnosis programs. Psychiatric Services 1999;50(1):109-12.
59. Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. Journal of Nervous and Mental Disease 1995;183(9):566-76.
60. Kavanagh DJ, Young R, White A, Saunders JB, Wallis J, Shockley N, et al.A brief motivational intervention for substance misuse in recent-onset psychosis. Drug and Alcohol Review 2004;23(2):151-5.
61. Kemp R, Harris A, Vurel E, Sitharthan T. Stop using stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australasian Psychiatry 2007;15(6):490-3. [MEDLINE: 17852064]
62. Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental illness and substance use disorders: a clinical trial. Journal of Nervous and Mental Disease 1993;181(2):86-90.
63. Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O'Connor JJ, et al.A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophrenia Research 2013;143(1):138-42.
64. Maloney MP. Reducing criminal recidivism in jail-incarcerated mothers with co-occurring disorders. Manuscript kindly provided by Dr Maloney - no further details given.
65. McDonell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, et al.Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. American Journal of Psychiatry 2013;170(1):94-101.
66. NCT00809770. Contingency management of psychostimulant abuse in the severely mentally ill. ClinicalTrials.gov 2008.
67. Weiss RD. Contingency management for patients with serious mental illness and stimulant dependence. American Journal of Psychiatry 2013;170(1):6-8.
68. Calsyn RJ, Yonker RD, Lemming MR, Morse GA, Klinkenberg WD. Impact of assertive community treatment and client characteristics on criminal justice outcomes in dual disorder homeless individuals. Criminal Behaviour and Mental Health 2005;15(4):236-48.
69. Fletcher TD, Cunningham JL, Calsyn RJ, Morse GA, Klinkenberg WD. Evaluation of treatment programs for dual disorder individuals: modeling longitudinal and mediation effects. Administration and Policy in Mental Health 2008;35(4):319-36. [MEDLINE: 18506618]
70. Morse GA, Calsyn RJ, Klinkenberg WD, Cunningham J, Lemming MR. Integrated treatment for homeless clients with dual disorders: a quasi-experimental evaluation. Journal of Dual Diagnosis 2008;4(3):219-37.
71. Morse GA, Calsyn RJ, Klinkenberg WD, Helminiak TW, Wolff N, Drake RE, et al.Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. Community Mental Health Journal 2006;42(4):377-404.
72. Naeem F, Kingdon D, Turkington D. Cognitive behaviour therapy for schizophrenia in patients with mild to moderate substance misuse problems. Cognitive Behaviour Therapy 2005;34(4):207-15.
73. Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. British Journal of Psychiatry 2002;180:523-7.
74. Nagel T, Robinson G, Condon J, Trauer T. Approach to treatment of mental illness and substance dependence in remote indigenous communities: results of a mixed methods study. Australian Journal of Rural Health 2009;17(4):174-82. [MEDLINE: 19664081]
75. Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. Journal of Nervous and Mental Disease 1999;187(10):630-5.
76. Tracy K, Babuscio T, Nich C, Kiluk B, Carroll KM, Petry NM, Rounsaville BJ. Contingency management to reduce substance use in individuals who are homeless with co-occurring psychiatric disorders. American Journal of Drug and Alcohol Abuse 2007;33(2):253-8. [MEDLINE: 17497548]
77. Audier C, Mulder CL, Staring A, Van Der Hoorn BE, Hakkaart-vanRoijen L, Blanken P. Money for medication: A randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with a psychotic disorder and co-morbid substance abuse. Schizophrenia Bulletin 2011;1:294-5.
78. Bachmann KM, Moggi F, Hirsbrunner HP, Donati R, Brodbeck J, Hirsbrunner H. An integrated treatment program for dually diagnosed patients. Psychiatric Services 1997;48(3):314-6.
79. Bagoien G, Bjorngaard J, Ostensen C, Romundstad P, Morken G. Motivational interviewing to patients with comorbid substance use admitted to an acute psychiatric department. Psychiatrische Praxis 2011;38:S10.
80. Bagoien G, Bjorngaard JH, Ostensen C, Reitan SK, Romundstad P, Morken G. The effects of motivational interviewing on patients with comorbid substance use admitted to a psychiatric emergency unit - a randomised controlled trial with two year follow-up. BMC Psychiatry 2013;13:93. [PUBMED: 23517244]
81. Barrowclough C, Haddock G, Lobban F, Jones S, Siddle R, Roberts C, Gregg L. Group cognitive-behavioural therapy for schizophrenia. British Journal of Psychiatry 2006;189:527-32.
82. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkotter J, Hambrecht M, Pukrop R. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatrica Scandinavica 2004;110(1):21-8.
83. Beebe LH, Smith K, Burk R, McIntyre K, Dessieux O, Tavakoli A, et al.Motivational intervention increases exercise in schizophrenia and co-occurring substance use disorders. Schizophrenia Research 2012;135(1-3):204-5.
84. Bell MD. Cognitive remediation with work therapy in the initial phase of substance abuse treatment. Schizophrenia Bulletin 2011;Suppl 1:296.
85. Bennett ME, Bellack AS, Gearon JS. Treating substance abuse in schizophrenia: An initial report. Journal of Substance Abuse Treatment 2001;20:163-75.
86. Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomised controlled trial. International Clinical Psychopharmacology 1999;14(3):177-80.
87. Biegel DE, Beimers D, Stevenson LD, Ronis RJ, Boyle P. Predictors of referral to supported employment among consumers with co-occurring mental and substance use disorders. Community Mental Health Journal 2009;45(6):427-38.
88. Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial of cognitive behavioural treatment of panic in alcoholic inpatients with comorbid panic disorder. Addictive Behaviours 2000;25(4):593-97.
89. Caplan B, Schutt RK, Turner WM, Goldfinger SM, Seidman LJ. Change in neurocognition by housing type and substance abuse among formerly homeless seriously mentally ill persons. Schizophrenia Research 2006;83(1):77-86. [MEDLINE: 16504484]
90. Carey KB, Purnine DM, Maisto SA, Carey MP. Enhancing readiness-to-change substance abuse in persons with schizophrenia. A four-session motivation-based intervention. Behaviour Modification 2001;25(3):331-84.
91. Carey MP, Carey KB, Maisto SA, Gordon CM, Schroder KEE, Vanable PA. Reducing HIV-risk behavior among adults receiving outpatient psychiatric treatment: Results from a randomized controlled trial. Journal of Consulting and Clinical Psychology 2004;72(2):252-68.
92. Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. American Journal of Drug and Alcohol Abuse 1991;17(3):229-47.
93. Carroll JFX, McGinley JJ. Managing MICA clients in a modified therapeutic community with enhanced staffing. Journal of Substance Abuse Treatment 1998;15(6):565-77.
94. Ceron D, Mondoni S, Malbergier A, Silva G. Schizophrenia: the influence of acupuncture on cocaine addicted patients. Conference presentation to 153rd Annual Meeting of the APA, May 13-18, Chicago. 2000.
95. Cheng AL, Lin H, Kasprow W, Rosenheck RA. Impact of supported housing on clinical outcomes: analysis of a randomized trial using multiple imputation technique. Journal of Nervous and Mental Disease 2007;195(1):83-8. [MEDLINE: 17220745]
96. Clark RE. Family support and substance use outcomes for persons with mental illness and substance use disorders. Schizophrenia Bulletin 2001;27(1):93-101.
97. Clarke GN, Herinckz HA, Kinney RF, Paulson RI, Cutler DL, Lewis K, Oxman E. Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: Findings from a randomized trial of two ACT programs vs. usual care. Mental Health Services Research 2000;2(3):155-64.
98. Conrad KJ, Lutz G, Matters MD, Donner L, Clark E, Lynch P. randomized trial of psychiatric care with representative payeeship for persons with serious mental illness. Psychiatric Services 2006;57(2):197-204. [MEDLINE: 16452696]
99. Craig TKJ, Johnson S, McCrone P, Afuwape S, Hughes E, Gournay K, et al.Integrated care for co-occurring disorders: psychiatric symptoms, social functioning, and service costs at 18 months. Psychiatric Services 2008;59(3):276-82. [MEDLINE: 18308908]
100. Crump MT, Milling RN. The efficacy of substance abuse education among dual-diagnosis patients. Journal of Substance Abuse Treatment 1996;13(2):141-4.
101. D'Ercole A, Struening E, Curtis JL, Millman EJ, Morris A. Effects of diagnosis, demographic characteristics, and case management on rehospitalization. Psychiatric Services 1997;48(5):682-8.
102. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999;21(2):195-202.
103. Daley DC, Ihsan MSW, Salloum MPH, Zuckoff MA, Kirisci L, Thase ME. Increasing treatment adherence among outpatients with depression and cocaine dependence: Results of a pilot study. American Journal of Psychiatry 1998;155(11):1611-3.
104. DeMarce JM, Lash SJ, Stephens RS, Grambow SC, Burden JL. Promoting continuing care adherence among substance abusers with co-occurring psychiatric disorders following residential treatment. Addictive Behaviors 2008;33(9):1104-12. [MEDLINE: 18573617]
105. Drake R E, Xie X, McHugo GJ, Shumway M. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders. Biological Psychiatry 2004;56(November 15):749-56.
106. Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmsetter B. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin. 2006;32(3):464-73.
107. Drebing CE, Van Ormer EA, Krebs C, Rosenheck R, Rounsaville B, Herz L, Penk W. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. Journal of Applied Behavior Analysis 2005;38(3):359-72.
108. Drebing CE, Van Ormer EA, Mueller L, Hebert M, Penk WE, Petry NM, et al.Adding contingency management intervention to vocational rehabilitation: outcomes for dually diagnosed veterans. Journal of Rehabilitation Research and Development 2007;44(6):851-65. [MEDLINE: 18075942]
109. Eberhard S, Nordstrom G, Hoglund P, Ojehagen A. Secondary prevention of hazardous alcohol consumption in psychiatric out-patients: a randomised controlled study. Social Psychiatry and Psychiatric Epidemiology 2009;12:1013-21.
110. Essock SM, Kontos N. Implementing assertive community treatment teams. Psychiatric Services 1995;46(7):679-83.
111. Faber G, Smid HGOM, Van Gool AR, Wunderink L, Van Den Bosch RJ, Wiersma D. Continued cannabis use and outcome in first-episode psychosis: Data from a randomized, open-label, controlled trial. Journal of Clinical Psychiatry 2012;73(5):632-8.
112. Fisher MS, Bentley KJ. Two group therapy models for clients with a dual diagnosis of substance abuse and personality disorder. Psychiatric Services 1996;47(11):1244-50.
113. De Leon G, Sacks S, Staines G, McKendrick K. Modified therapeutic community for homeless mentally ill chemical abusers: treatment outcomes. American Journal of Drug and Alcohol Abuse 2000;26(3):461-80.
114. French MT, Sacks S, De Leon G, Staines G, McKendrick K. Modified therapeutic community for mentally ill chemical abusers: outcomes and costs. Evaluation and the Health Professions 1999;22(1):60-85.
115. Giannini AJ, Underwood NA, Condon M. Acute ketamine intoxication treated by haloperidol: a preliminary study. American Journal of Therapeutics 2000;7(6):389-91.
116. Godley SH, Finch M, Dougan L, McDonnell M, McDermeit M, Carey A. Case management for dually diagnosed individuals involved in the criminal justice system. Journal of Substance Abuse Treatment 2000;18(2):137-48.
117. Goldstein G, Haas GL, Shemansky WJ, Barnett B, Salmon-Cox S. Rehabilitation during alcohol detoxication in comorbid neuropsychiatric patients. Journal of Rehabilitation Research and Development 2005;42(2):225-34. [MEDLINE: 15944887]
118. Green A, Tohen M, Strakowski SM, Lieberman JA, Glick ID, Clarke SW, HGDG study group. Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine versus haloperidol. CSG Register of Trials. 2001.
119. Havassy BE, Shropshire MS, Quigley LA. Effects of substance dependence on outcomes of patients in a randomized trial of two case management models. Psychiatric Services 2000;51(5):639-44.
120. Hayes RA, Andrews N, Baron-Jeffrey M, Conley C, Gridley K, Norman R, Wright G. Service enhancement to a dual-diagnosis population: Mental Illness/Substance Abuse (MISA). Quality Management in Health Care 2003;12(3):133-50.
121. Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C. Promising treatment for women with comorbid PTSD and substance use disorders. American Journal of Psychiatry 2004;161(8):1426-32.
122. Herman SE, BootsMiller B, Jordan L, Mowbray CT, Brown G, Deiz N, et al.Immediate outcomes of substance abuse treatment within a state psychiatric hospital. Journal of Mental Health Administration 1997;24(2):126-38.
123. Herman SE, Frank KA, Mowbray CT, Ribisl K, Davidson WS, BootsMiller B, et al.Longitudinal effects of integrated treatment on alcohol use for persons with serious mental illness and substance use disorders. Journal of Behavioral Health Services and Research 2000;27(3):286-302.
124. Hulse GK, Tait RJ. Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug and Alcohol Review 2002;21(2):105-12.
125. Hurlburt MS, Hough RL, Wood PA. Effects of substance abuse on housing stability of homeless mentally ill persons in supported housing. Psychiatric Services 1996;47(7):731-6.
126. ISRCTN58667926. Impact - improving physical health and reducing substance use in severe mental illness: randomised controlled trial of a health promotion intervention. http://public.ukcrn.org.uk/ 2011.
127. James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychological Medicine 2004;34(6):983-90.
128. Jerrell JM, Wilson JL, Hiller DC. Issues and outcomes in integrated treatment programs for dual disorders. Journal of Behavioral Health Services & Research 2000;27(3):303-13.
129. Jones SH, Barrowclough C, Allott R, Day C, Earnshaw P, Wilson I. Integrated motivational interviewing and cognitive-behavioural therapy for bipolar disorder with comorbid substance use. Clinical Psychology & Psychotherapy 2011;18(5):426-37.
130. Judd PH, Thomas N, Schwartz T, Outcalt A, Hough R. A dual diagnosis demonstration project: treatment outcomes and cost analysis. Journal of Psychoactive Drugs 2003;35 Suppl 1:181-92.
131. Kasprow WJ, Rosenheck R, Frisman L, DiLella D. Residential treatment for dually diagnosed homeless veterans: a comparison of program types. American Journal on Addictions 1999;8(1):34-43.
132. Keet IPM, Hulstijn KP, de Haan L, Schippers G, Linszen D. Family motivational intervention: training motivational interviewing for family members of patients with schizophrenia, cannabis use and poor compliance. Schizophrenia Research 2006;86 Suppl 1:S149.
133. Kelly JF, McKellar JD, Moos R. Major depression in patients with substance use disorders: relationship to 12-step self-help involvement and substance use outcomes. Addiction 2003;98(4):499-508.
134. Lasser R, Matkovits-Gupta T, Cucchiaro J, Fairweather D, Young F, El-Bizri H, et al.The unique aspects of the realise program - a global development programme to assess the safety, efficacy and long-term impact of iloperidone in schizophrenia. International Journal of Neuropsychopharmacology 2000;3(1):S123.
135. Linehan MM, Schmidt H, Dimeff LA, Craft JC, Kanter J, Comtois KA. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. The American Journal on Addictions 1999;8(4):279-92.
136. Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS, Heagerty P, Kivlahan DR. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug and Alcohol Dependence 2002;67(1):13-26.
137. Magura S, Laudet AB, Mahmood D, Rosenblum A, Vogel HS, Knight EL. Role of self-help processes in achieving abstinence among dually diagnosed persons. Addictive Behaviours 2003;28(3):399-413.
138. Mangrum LF, Spence RT, Lopez M. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. Journal of Substance Abuse Treatment 2006;30(1):79-84.
139. Martino S, Carroll KM, O'Malley SS, Rounsaville BJ. Motivational interviewing with psychiatrically ill substance abusing patients. The American Journal on Addictions 2000;9(1):88-91.
140. Martino S, Carroll KM, Nich C, Rounsaville BJ. A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 2006;101(10):1479-92.
141. McGeary KA, Sacks S, McKendrick K, De Leon G. Service use and cost by mentally ill chemical abusers: differences by retention in a therapeutic community. Journal of Substance Abuse 2000;11(3):265-79.
142. McGurk SR, Mueser KT, Derosa TJ, Wolfe R. Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. Schizophrenia Bulletin 2009;35(2):319-35.
143. McHugo GJ, Drake RE, Teague GB, Xie H. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatric Services 1999;50(6):818-24.
144. McMurran M. Mental disorder, alcohol intoxification and violence. National Research Register 2002; Vol. Publication number #M0007054877, issue 2.
145. Mercer McFadden C, Drake RE, Brown NB, Fox RS. The Community Support Program demonstrations of services for young adults with severe mental illness and substance use disorders, 1987-1991. Psychiatric Rehabilitation Journal 1997;20(3):13-24.
146. Milby JB, Schumacher JE, McNamara C, Wallace D, Usdan S, McGill T, Michael M. Initiating abstinence in cocaine abusing dually diagnosed homeless persons. Drug & Alcohol Dependence 2000;60(1):55-67.
147. Morse GA, Calsyn RJ, Klinkenberg WD, Trusty ML, Gerber F, Smith R, et al.An experimental comparison of three types of case management for homeless mentally ill persons. Psychiatric Services 1997;48(4):497-503.
148. Mowbray CT, Jordan LC, Ribisl KM, Kewalramani A, Luke D, Herman S, Bybee D. Analysis of postdischarge change in a dual diagnosis population. Health and Social Work 1999;24(2):91-101.
149. Mueser KT, Essock SM, Drake RE, Wolfe RS, Frisman L. Rural and urban differences in patients with a dual diagnosis. Schizophrenia Research 2001;48(1):93-107.
150. Mueser KT, Glynn SM, Cather C, Zarate R, Fox L, Feldman J, et al.Family intervention for co-occurring substance use and severe psychiatric disorders: participant characteristics and correlates of initial engagement and more extended exposure in a randomized controlled trial. Addictive Behaviors 2009;34(10):867-77. [MEDLINE: 19375870]
151. Mueser K, Glynn SM, Xie H, Zarate R, Cather C, Fox L, et al.Family psychoeducation with patients who have co-occurring substance use disorders and severe mental illness. Schizophrenia Research 2010;117(2-3):121.
152. Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF, et al.A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatric disorders. Schizophrenia Bulletin 2013;39(3):658-72. [MEDLINE: 22282453]
153. NCT00043693. Family intervention for SMI and substance use disorder. http://www.clinicaltrials.gov 2002.
154. NCT00316303. Effectiveness of the screen, test, immunize, reduce risk, and refer (stirr) intervention for people with both a mental and substance abuse disorder. http://clinicaltrials.gov 2009.
155. NCT00447720. HIV prevention among substance abusing SMI. http://www.clinicaltrials.gov 2007.
156. NCT00495911. A randomized controlled trial of individual therapy for first episode psychosis. http://www.clinicaltrials.gov 2007.
157. NCT01167556. Family motivational intervention in schizophrenia. http://ClinicalTrials.gov/show/NCT01167556 2006.
158. NCT01361698. Illness Management and Recovery (IMR) in Danish community mental health centres. http://ClinicalTrials.gov/show/NCT01361698 2011.
159. Nuijten M, Blanken P, Van Der Hoorn B, Van Den Brink W, Hendriks V. A randomised controlled trial of outpatient versus inpatient integrated treatment of dual diagnosis patients: A failed but informative study. Mental Health and Substance Use: Dual Diagnosis 2012;5(2):132-47.
160. Nuttbrock L, Ng-Mak DS, Rahav M, Rivera JJ. Pre- and post-admission attrition of homeless, mentally ill chemical abusers referred to residential treatment programs. Addiction 1997;92(10):1305-16.
161. Nuttbrock LA, Rahav M, Rivera JJ, Ng-Mak DS, Link BG. Outcomes of homeless mentally ill chemical abusers in community residences and a therapeutic community. Psychiatric Services 1998;49(1):68-76.
162. Rahav M, Rivera JJ, Nuttbrock L, Ng Mak D. Characteristics and treatment of homeless, mentally ill, chemical-abusing men. Journal of Psychoactive Drugs 1995;27(1):93-103.
163. Otto-Salaj LL, Kelly JA, Stevenson LY, Hoffman R, Kalichman SC. Outcomes of a randomized small-group HIV prevention intervention trial for people with serious mental illness. Community Mental Health Journal 2001;37(2):123-43.
164. Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: Twelve-step and self-management and recovery training. The American Journal of Drug and Alcohol Abuse 2003;29(2):359-83.
165. Penn PE, Brooks AJ. Five years, twelve steps, and REBT in the treatment of dual diagnosis. Journal of Rational-Emotive & Cognitive-Behavior Therapy 2000;18(4):197-208.
166. Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Christensen T, Krarup G, et al.Substance abuse in first-episode schizophrenia-spectrum disorders. Schizophrenia Research 2006;86 Suppl 1:S44.
167. Petersen L, Nordentoft M, Bertelsen M, Thorup A. Does cannabis abuse determine outcome among patients with first episode psychosis. Results from the OPUS-trial. Schizophrenia Bulletin 2007;33(2):453.
168. Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Krarup G, Ostergard T, et al.Substance abuse and first-episode schizophrenia-spectrum disorders The Danish OPUS trial. Early Intervention in Psychiatry 2007;1(1):88-96.
169. Petrakis IL, Poling J, Levinson C, Nich C, Carroll C, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry 2005;57(10):1128-37.
170. Rahav M, Rivera JJ, Nuttbrock L, Ng-Mak D, Sturz EL, Link BG, et al.Characteristics and treatment of homeless, mentally ill, chemical-abusing men. Journal of Psychoactive Drugs 1995;27(1):93-103. [MEDLINE: 95325981]
171. Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: first step toward developing effective treatments. Alcoholism: Clinical and Experimental Research 2001;25(2):210-20.
172. Ries RK, Dyck DG, Short R, Srebnik D, Fisher A, Comtois KA. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatric Services 2004;55(4):445-7.
173. Rosenheck RA, Neale MS. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. Archives of General Psychiatry 1998;55(5):459-66.
174. Rowe M, Bellamy C, Baranoski M, Wieland M, O'Connell MJ, Benedict P, et al.A peer-support, group intervention to reduce substance use and criminality among persons with severe mental illness. Psychiatric Services 2007;58(7):955-61. [MEDLINE: 17602012]
175. Sacks S, Sacks JY, McKendrick K, Banks S, Stommel J. Modified TC for MICA offenders: crime outcomes. Behavioral Sciences and the Law 2004;22(4):477-501.
176. Sacks JY, Sacks S, McKendrick K, Banks S, Schoeneberger M, Hamilton Z, et al.Prison therapeutic community treatment for female offenders: profiles and preliminary findings for mental health and other variables (crime, substance use and HIV risk). Journal of Offender Rehabilitation 2008;46(3-4):233-61.
177. Sullivan CJ, McKendrick K, Sacks S, Banks S. Modified therapeutic community treatment for offenders with MICA disorders: substance use outcomes. American Journal of Drug and Alcohol Abuse 2007;33(6):823-32.
178. Samele C, Walsh E, Gilvarry C, Manley C, Tattan T, Fahy T, et al.Non-alcohol substance misuse, outcome and intensive case management. European Psychiatry 2002;17 Suppl 1:216s.
179. Santa Ana EJ, Wulfert E, Nietert PJ. Efficacy of group motivational interviewing (GMI) for psychiatric inpatients with chemical dependence. Journal of Consulting and Clinical Psychology 2007;75(5):816-22. [MEDLINE: 17907864]
180. Schaar I, Ojehagen A. Severely mentally ill substance abusers: an 18 month follow-up study. Social Psychiatry Psychiatric Epidemiology 2001;36(2):70-8.
181. Schmitz JM, Averill P, Sayre S, McCleary P, Moeller FG, Swann A. Cognitive-behavioral treatment of bipolar disorder and substance abuse: A preliminary randomized study. Addictive Disorders and Their Treatment 2002;1(1):17-24.
182. Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Experimental & Clinical Psychopharmacology 2000;8(4):509-17.
183. Siris SG, Mason SE, Bermanzohn PC, Shuwall MA. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacology Bulletin 1993;29(1):127-33.
184. Sitharthan T, Singh S, Kranitis P, Currie J, Freeman P, Murugesan G, et al.Integrated drug and alcohol intervention: development of an opportunistic intervention program to reduce alcohol and other substance use among psychiatric patients. Australian and New Zealand Journal of Psychiatry 1999;33(5):676-83. [MEDLINE: PMID 10544991]
185. Smeerdijk M, Keet R, De Haan L, Schippers G, Linszen D. Family motivation intervention in early onset psychosis and cannabis abuse: a randomized clinical trial. Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA. Oxford Univ Press, 371.
186. Smeerdijk M, Keet R, Dekker N, Van Raaij B, Krikke M, Koeter M, et al.Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent onset schizophrenia. Early Intervention in Psychiatry 2010;4 Suppl 1:6.
187. Smeerdijk M, Keet R, Dekker N, van RB, Krikke M, Koeter M, et al.Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial. Psychological Medicine 2012;42(8):1627-36.
188. Swanson JW, Swartz MS, Borum R, Hiday VA, Wagner R, Burns BJ. Involuntary out-patient commitment and reduction of violent behaviour in persons with severe mental illness. British Journal of Psychiatry 2000;176:324-31.
189. Teague GB, Drake RE, Ackerson TH. Evaluating use of continuous treatment teams for persons with mental illness and substance abuse. Psychiatric Services 1995;46(7):689-95.
190. Hughes E, Wanigaratne S, Gournay K, Johnson S, Thornicroft G, Finch E, et al.Training in dual diagnosis interventions (the COMO Study): randomised controlled trial. BMC Psychiatry 2008;8:12. [MEDLINE: 18304310]
191. Johnson S, Thornicroft G, Afuwape S, Leese M, White IR, Hughes E, et al.Effects of training community staff in interventions for substance misuse in dual diagnosis patients with psychosis (COMO study): cluster randomised trial. British Journal of Psychiatry 2007;191(November):451-2. [MEDLINE: 17978327]
192. Thornicroft G. Prevention of admission to psychiatric hospital. A randomised controlled trial of service use, health and social care outcomes of a community mental health team intervention specific to dual diagnosis (psychosis and substance misuse) patients. http://www.controlled-trials.com. United Kingdom, 2007.
193. Timko C, Chen S, Sempel J, Barnett P. Dual diagnosis patients in community or hospital care: one-year outcomes and health care utilization and costs. Journal of Mental Health 2006;15(2):163-77.
194. Timko C, Sempel JM. Short-term outcomes of matching dual diagnosis patients' symptom severity to treatment intensity. Journal of Substance Abuse Treatment. 2004;26(3):209-18.
195. Ranger M, Tyrer P, Miloseska K, Fourie H, Khaleel I, North B, et al.Cost-effectiveness of nidotherapy for comorbid personality disorder and severe mental illness: randomized controlled trial. Epidemiologia e Psichiatria Sociale 2009;18(2):128-36. [MEDLINE: 19526744]
196. Tyrer P, Miloseska K, Whittington C, Ranger M, Khaleel I, Crawford M, et al.Nidotherapy in the treatment of substance misuse, psychosis and personality disorder: Secondary analysis of a controlled trial. Psychiatrist 2011;35(1):9-14.
197. Watt M, Stewart S, Birch C, Bernier D. Brief CBT for high anxiety sensitivity decreases drinking problems, relief alcohol outcome expectancies, and conformity drinking motives: evidence from a randomized controlled trial. Journal of Mental Health 2006;15(6):683-95.
198. Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, et al.Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. Journal of Mental Health Policy and Economics 2009;12(1):33-46. [MEDLINE: 19346565]
199. Weiss R D, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, Hennene JA. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. Journal of Clinical Psychiatry 2000;61(5):361-7.
200. Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, et al.A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. American Journal of Psychiatry 2007;164(1):100-7.
201. Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff FS, Gallop RJ, Fitzmaurice GM. A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. Drug & Alcohol Dependence 2009;104(3):212-9.
202. Weiss, R. Modifying group therapy for bipolar substance abusers. NCT00227838. http://www.clinicaltrials.gov 2005.
203. Worley MJ, Trim RS, Tate SR, Hall JE, Brown SA. Service utilization during and after outpatient treatment for comorbid substance use disorder and depression. Journal of Substance Abuse Treatment 2010;39(2):124-31.
204. Xie H, McHugo GJ, Fox MB, Drake RE. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders. Psychiatric Services 2005;56(10):1282-7.
205. Xie H, McHugo GJ, Helmstetter BS, Drake RE. Three-year recovery outcomes for long-term patients with co-occurring schizophrenic and substance use disorders. Schizophrenia Research 2005;75(2-3):337-48.
206. Xie H, Drake R, McHugo G. Are there distinctive trajectory groups in substance abuse remission over 10 years? An application of the group-based modeling approach. Administration and Policy in Mental Health and Mental Health Services 2006;33(4):423-32.
207. Meister K, Rietschel L, Burlon M, Jannsen H, Bock T, Wegscheider K, et al.A cluster-randomized, parallel group, observer blind trial of a group based motivational-behavioural therapy for young people with psychosis and substance use disorder. Early Intervention in Psychiatry 2010;4 Suppl 1:163.
208. Meister, K. Comorbid psychosis and addiction. Epidemiology, explanatory models and evaluation of motivational behavioural group therapy [Komorbidität psychose und sucht. Epidemiologie, erklärungsmodelle und evaluation einer motivational-verhaltenstherapeutischen gruppentherapie]. Dissertation, University of Hamburg 2010.
209. Odom AE. A randomized study of integrated outpatient treatment and assertive community treatment for patients with comorbid mental illness and substance use disorders: comparing treatment outcome for domiciled and homeless patients [PhD thesis]. New School University, 2005.
210. ACTRN12610000249055. A randomised control trial of a group based intervention and relapse prevention package for substance misuse and psychosis. Australian New Zealand Clinical Trials Registry 2010.
211. Bennett M, Bellack AS, Dixon L. Treatment of alcohol use disorders in people with severe mental illness. Schizophrenia Bulletin 2007;33(2):421.
212. NCT00280813. Treatment of alcohol use disorders in schizophrenia. http://www.clinicaltrials.gov 2006.
213. Bennett M, Bellack A, Dixon L, Brown C. The effects of a group based behavioral approach to substance misuse and schizophrenia. Schizophrenia Bulletin 2011;1:296.
214. NCT00295139. Behavioral treatment of drug abuse in SPMI patients. http://www.clinicaltrials.gov 2006.
215. ISRCTN33576045. Contingency intervention for reduction of cannabis in early psychosis -circle. http://www.controlled-trials.com 2011.
216. ISRCTN33576045. Randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention for reduction of cannabis use and of relapse in early psychosis. Circle. http://public.ukcrn.org.uk/ 2012.
217. NCT00783185. Dual diagnosis (psychosis and cannabis misuse): comparison of specialized treatment versus unspecified treatment. http://www.clinicaltrials.gov 2008.
218. NCT00798109. Effect of motivational therapy on schizophrenia with cannabis misuse. http://www.clinicaltrials.gov 2008.
219. NCT01478815. Contingency management for persons with severe mental illness. http://ClinicalTrials.gov/show/NCT01478815 2011.
220. NCT01567943. Contingency management of alcohol abuse in the severely mentally ill. http://ClinicalTrials.gov/show/NCT01567943 2012.
221. Smith S, Greenwood K, Atakan Z, Sood P, Ohlsen R, Papanastasiou E, et al.The impact study - motivating a change in health behaviour. European Psychiatry. 2011.
222. U1111-1119-5851. Evaluation of an integrative therapy approach for the comorbidity of psychosis and addiction. http://www.drks.de/DRKS00000671 2011.
223. Verstappen N, Henquet C. Effects and indicators of CBT for cannabis use in psychosis [Studie naar 'Behandeling cananbisgebruik en psychose']. http://www.trialregister.nl/trialreg/index.asp 2007.
224. Barrowclough C, Lobbanl F, Warburton J, Choudhry I, Gregg L, Wood H, et al.Helper recap: Rethinking choices after psychosis - a phase specific psychological therapy for people with problematic cannabis use following a first episode of psychosis. Early Intervention in Psychiatry 2010;4 Suppl 1:161.
225. Worrell L. Helper programme (substance misuse)- a phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis (recap). http://public.ukcrn.org.uk 2011.
226. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research 1992;6(3):201-8.
227. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. [: TP020600]
228. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al.The revised CONSORT statement for reporting randomized trial: explanation and elaboration. Annals of Internal Medicine 2001;134(8):663-94.
229. Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1982;39:784-8.
230. Appleby L, Dyson V, Altman E, Luchins DJ. Assessing substance use in multiproblem patients: reliability and validity of the Addiction Severity Index in a mental hospital population. Journal of Nervous & Mental Disease 1997;185(3):159-65.
231. Asberg M, Montgomery SA, Perris C, et al.A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica Supplement 1978;271:5-27.
232. Baker AL, Hiles SA, Thornton LK, Hides L, Lubman DI. A systematic review of psychological interventions for excessive alcohol consumption among people with psychotic disorders. Acta Psychiatrica Scandinavica 2012;126(4):243-55.
233. Barrowclough C, Haddock G, Fitzsimmons M, Johnson R. Treatment development for psychosis and co-occurring substance misuse: A descriptive review. Journal of Mental Health 2006;15(6):619-32.
234. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technique. Postgraduate Medicine 1972;52(6):81-5.
235. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al.Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9.
236. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale: the development and validation of a scale of social adjustment for use in family intervention programmes with schizophrenic patients. British Journal of Psychiatry 1990;157(December):853-9.
237. Bland JM, Kerry SM. Trials randomised in clusters. BMJ 1997;315(7108):600.
238. Bogenschutz MP, Geppert CM, George J. The role of twelve-step approaches in dual diagnosis treatment and recovery. American Journal on Addictions 2006;15(1):50-60.
239. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
240. Bond GR, Miller LD, Krumwied RD, Ward RS. Assertive case management in three CMHCs: a controlled study. Hospital and Community Psychiatry 1988;39(4):411-8.
241. Bond GR, Witheridge TF, Dincin J, Wasmer D, Webb J, DeGraaf-Kaser R. Assertive community treatment for frequent users of psychiatric hospitals in a large city: a controlled study. American Journal of Community Psychology 1990;18(6):865-91.
242. Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica 2007;116(6):403-18.
243. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al.Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry 2012;169(4):389-96.
244. Carey KB, Cocco KM, Simons JS. Concurrent validity of clinicians' rating of substance abuse among psychiatric outpatients. Psychiatric Services 1996;47(8):842-7.
245. Carra G, Johnson S. Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review. Social Psychiatry & Psychiatric Epidemiology 2009;44(6):429-47.
246. Chanut F, Brown TG, Dongier M. Motivational interviewing and clinical psychiatry. Canadian Journal of Psychiatry 2005;50(9):548-54.
247. Cleary M, Hunt GE, Matheson S, Walter G. Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: systematic review. Journal of Advanced Nursing 2009;65(2):238-58.
248. Cleary M, Hunt GE, Horsfall J. Conducting efficient literature searches. Strategies for mental health nurses. Journal of Psychosocial Nursing & Mental Health Services 2009;47(11):34-41.
249. Corse SJ, Hirschinger NB, Zanis D. The use of the Addiction Severity Index with people with severe mental illness. Psychiatric Rehabilitation Journal 1995;19(1):9-18.
250. Darke S, Ward J, Hall W, Heather N, Wodak A. The Opiate Treatment Index (OTI) Researchers Manual. Technical report No. 11. Sydney: National Drug & Alcohol Research Centre, 1991.
251. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. British Journal of Addiction 1992;87(5):733-42.
252. David A, Buchanan A, Reed A, Almeida O. The assessment of insight in psychosis. British Journal of Psychiatry 1992;161(November):599-602.
253. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
254. Derogatis LR, Lipman RS, Covi L. SCL-90: An outpatient psychiatric rating scale: Preliminary report. Psychopharmacology Bulletin 1973;9(1):13-27.
255. Derogatis LR, Yevzeroff H, Wittelsberger B. Social class, psychological disorder, and the nature of the psychpathologic indicator. Journal of Consulting and Clinical Psychology 1975;43(2):183-91.
256. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychological Medicine 1983;13(3):595-605.
257. Derogatis LR. SCL-90-R: Administration, scoring & procedures manual-II. Towson, MD: Clinical Psychometric Research, 1983.
258. Divine GW, Brown JT, Frazer LM. The unit analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
259. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, et al.The 2009 schizophrenia PORTpsychosocial treatment recommendations and summary statements. Schizophrenia Bulletin 2010;36(1):48-70.
260. Dohrenwend BP, Shrout PE, Egri G, et al.Nonspecific psychological distress and other dimensions of psychopathology. Measures for use in the general population. Archives of General Psychiatry 1980;37(11):1229-36.
261. Donald M, Downer J, Kavanagh D. Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. Social Science and Medicine 2005;60(6):1371-83.
262. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
263. Drake RE, Bartels SJ, Teague GB, Noordsy DL, Clark RE. Treatment of substance abuse in severely mentally ill patients. Journal of Nervous and Mental Disease 1993;181(10):606-11.
264. Drake RE, Mueser KT, Clarke RE, Wallach MA. The course, treatment, and outcome of substance disorder in persons with severe mental illness. American Journal of Orthopsychiatry 1996;66(1):42-51.
265. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. A review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin 1998;24(4):589-608.
266. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal 2004;27(4):360-74.
267. Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse and Treatment 2008;34(1):123-38.
268. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM III-R). Diagnostic & Statistical Manual of Mental Disorders (DSM III-R). 3rd Edition. Washington D.C: American Psychiatric Association, 1987.
269. APA 1994. Diagnostic & Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: APA, 1994.
270. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. American Journal of Psychiatry 2008;165(2):179-87.
271. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
272. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
273. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33(6):766-71.
274. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
275. Goldman HH, Skodal AE, Lave TR. Revising Axis V for DSM-IV: a review of measures of social functioning. Americal Journal of Psychiatry 1992;149(9):1148-56.
276. Green RS, Gracely EJ. Selecting a rating scale for evaluating services to the chronically mentally ill. Community Mental Health Journal 1987;23(2):91-102.
277. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Americal Journal of Psychiatry 2007;164(3):402-8.
278. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clinical Psychology Review 2007;27(4):494-510.
279. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
280. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23(February):56-62.
281. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
282. Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: Higgins JPT, Green S editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2006.
283. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
284. Hodgins DC, el-Guebaly N. More data on the Addiction Severity Index. Reliability and validity with the mentally ill substance abuser. Journal of Nervous & Mental Disease 1992;180(3):197-201.
285. Horn JL, Wanberg KW, Foster FM. The Alcohol Use Inventory. Minneapolis, MN: National Computer Systems, 1987.
286. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harvard Review of Psychiatry 2009;17(1):24-34.
287. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophrenia Research 2002;54(3):253-64.
288. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
289. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization, 1992.
290. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000524]
291. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD008712.pub2]
292. Kapur S, Mizrahi R, Li M. From dopamine to salience to pyschosis - linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 2005;79:59-68.
293. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
294. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
295. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors 2012;37(1):11-24.
296. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35(1):217-38.
297. Lai HM, Sitharthan T, Huang QR. Exploration of the comorbidity of alcohol use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Substance Abuse 2012;33(2):138-45.
298. Lai HM, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. American Journal of Drug & Alcohol Abuse 2012;38(6):567-74.
299. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Evaluation and Program Planning 1979;2(2):197-207.
300. LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review andre-analysis of clinical evidence. Psychopharmacology 1995;121:407-27.
301. Lehman AF. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988;11(1):51-62.
302. Lehman AF. Evaluating Quality of Life for Persons with Severe Mental Ilness: Assessment Toolkit. Cambridge, Mass: The Evaluation Center at Health Services Research Institute, 1995.
303. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187(October):366-71. [PUBMED: 16199797]
304. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
305. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
306. Lowe AL, Abou-Saleh MT. The British experience of dual diagnosis in the national health service. Acta Neuropsychiatrica 2004;16(1):41-6.
307. Lubman DI, King JA, Castle DJ. Treating comorbid substance use disorders in schizophrenia. International Review of Psychiatry 2010;22(2):191-201.
308. Lukoff D, Nuechterlein KH, Ventura J. Manual for expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bulletin 1986;12(4):594-602.
309. Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000050]
310. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176(March):249-52.
311. McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. Journal of Nervous and Mental Disease 1995;183(12):762-7.
312. McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry 2013;70(3):319-24.
313. McLellan AT, Luborsky L, Woody GE, O'Brien C. An improved evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease 1980;168(1):26-33.
314. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al.The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992;9(3):199-213.
315. Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific community -oriented treatment of early psychosis an economically viable method of improving outcome?. Acta Psychiatrica Scandinavica 1999;100(1):47-55.
316. Miller WR, Marlatt AG. Brief Drinker Profile (BDP) Interview Booklet. Odessa, FL: Psychological Assessment Resources, Inc, 1987.
317. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
318. Montgomery SA, Asberg M, Taylor P, Montgomery D. Development of a schizophrenia scale sensitive to change. Neuropharmacology 1978;17(12):1061-3.
319. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134(April):382-9.
320. Mueser KT, Drake RE, Clark RE, McHugo GJ, Mercer-McFadden C, Ackerson TH. Evaluating substance abuse in persons with severe mental illness. Cambridge, MA: Human Services Research Institute, 1995.
321. Mueser KT. Clinical interventions for severe mental illness and co-occurring substance use disorder. Acta Neuropsychiatrica 2004;16(1):26-35.
322. Mueser KT, Drake RE, Sigmon SC, Brunette MF. Psychosocial interventions of adults with severe mental illnesses and co-occurring substance use disorders: a review of specific interventions. Journal of Dual Diagnosis 2005;1(2):57-82.
323. Murthy P, Chand P. Treatment of dual diagnosis disorders. Current Opinion in Psychiatry 2012;25(3):194-200.
324. NICE. Psychosis with coexisting substance misuse. Assessment and management in adults and young people. National Clinical Guideline 120. London: British Psychological Society and the Royal College of Psychiatrists, 2011:1-322. [: http://www.nice.org.uk/CG120]
325. Norman RM, Malla AK, Cortese L, Diaz F. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Research 1996;19(1):73-85.
326. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10(3):799-812.
327. Pluddemann A, Dada S, Parry CD, Kader R, Parker JS, Temmingh H, et al.Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. African Journal of Psychiatry 2013;16(1):45-9.
328. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry 1999;45(1):7-12.
329. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. Journal of Nervous & Mental Disease 2012;200(10):832-9.
330. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264(19):2511-8.
331. Rollnick S, Heather N, Gold R, Hall W. Development of a short 'readiness to change' questionnaire for use in brief opportunistic interventions among excessive drinkers. British Journal of Addiction 1992;87(5):743-54.
332. Schmidt LM, HesseM, Lykke J. The impact of substance use disorders on the course of schizophrenia - a 15-year follow-up study: dual diagnosis over 15 years. Schizophrenia Research 2011;130(1-3):228-33.
333. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
334. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
335. Seibyl JP, Satel SL, Dominic A, Southwick SM, Krystal JH, Charney DS. Effects of cocaine on hospital course in schizophrenia. Journal of Nervous and Mental Disease 1993;181(1):30-7.
336. Seivewright N, McMahon C, Egleston P. Stimulant use still going strong: revisiting .misuse of amphetamines and related drugs. Advances in Psychiatric Treatment 2005;11(July):262-9.
337. Siegfried N. A review of comorbidity: major mental illness and problematic substance use. Australian and New Zealand Journal of Psychiatry 1998;32(5):707-17.
338. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of Life Research 2004;13(2):299-310.
339. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R - Patient Edition (SCID-P). Washington, DC: American Psychiatric Press, 1990.
340. Stein LI, Test MA. Alternative to mental hospital treatment: 1 Conceptual model, treatment program, and clinical evaluation. Archives of General Psychiatry 1980;37(4):392-7.
341. Tiet QQ, Mausbach B. Treatment for patients with dual diagnosis: a review. Alcoholism: Clinical and Experimental Research 2007;31(4):513-36.
342. Todd J, Green G, Harrison M, Ikuesan BA, Self C, Baldacchino A, Sherwood S. Defining dual diagnosis of mental illness and substance misuse: some methodological issues. Journal of Psychiatric and Mental Health Nursing 2004;11(1):48-54.
343. Tsuang J, Fong TW, Lesser I. Psychosocial treatment of patients with schizophrenia and substance abuse disorders. Addictive Disorders and Their Treatment 2006;5(2):53-66.
344. Turpin DL. CONSORT and QUOROM guidelines for reporting randomized clinical trials and systematic reviews. American Journal of Orthodontics and Dentofacial Orthodapedics 2005;128(6):681-6.
345. Tyrer P, Owen RT, Cicchetti DV. The brief scale for anxiety: a subdivision of the Comprehensive Psychopathological Rating Scale. Journal of Neurology, Neurosurgery and Psychiatry 1984;47(9):970-5.
346. Tyrer P, Weaver T. Desperately seeking solutions: the search for appropriate treatment for comorbid substance misuse and psychosis. Psychiatric Bulletin 2004;28(1):1-2.
347. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
348. Warren JI, Stein JA, Grella CE. Role of social support and self-efficacy in treatment outcomes among clients with co-occurring disorders. Drug and Alcohol Dependence. 2007;89(2-3):267-74.
349. Wieduwilt KM, Jerrell JM. The reliability and validity of the SAS-SMI. Journal of Psychiatric Research 1999;33(2):105-12.
350. Wing JK, Babor T, Brugha T, et al.SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 1990;47(6):589-93.
351. Wing JK, Curtis R, Beevor A. The Health of the Nation Outcome Scales. London: Royal College of Psychiatrists, 1996.
352. Work Group on Substance Use Disorders, Kleber HD, Weiss RD, Anton RF, Rounsaville BJ, George TP, Strain EC, et al.Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Americal Journal of Psychiatry 2007;164 Suppl:5-123.
353. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
354. Young RC, Briggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978;133(November):429-35.
355. Zanis DA, McLellan AT, Corse S. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders?. Community Mental Health Journal 1997;33(3):213-27.
356. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, et al.Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. Journal of Psychiatric Practice 2005;11(5):315-39.
357. Cleary M, Hunt G, Matheson S, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD001088.pub2]
358. Ley A, Jeffery DP, McLaren S, Siegfried N. Treatment programmes for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001088]